Optinose_logo_RGB.png
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
May 05, 2021 07:00 ET | Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
April 28, 2021 08:30 ET | Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...
Optinose_logo_RGB.png
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2021 16:15 ET | Optinose, Inc.
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
March 03, 2021 07:00 ET | Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
February 17, 2021 17:23 ET | Optinose, Inc.
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41st Annual Health Care Conference on March 4, 2021 YARDLEY, Pa., Feb. 17, 2021 ...
Optinose_logo_RGB.png
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 25, 2021 16:30 ET | Optinose, Inc.
YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose_logo_RGB.png
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2020 10:00 ET | Optinose, Inc.
YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose_logo_RGB.png
Optinose Announces Changes to Board of Directors
December 01, 2020 16:30 ET | Optinose, Inc.
YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
November 05, 2020 07:00 ET | Optinose, Inc.
Company reports third quarter 2020 XHANCE net revenue of $15.4 million New prescriptions of XHANCE increased 23% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m....
Optinose_logo_RGB.png
Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
October 22, 2020 07:00 ET | Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 78% Compared to Third Quarter 2019 and 50% Compared to Second Quarter 2020 Conference Call and Webcast to be held November 5, 2020 at 8:00 a.m. Eastern...